WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI(TM) (lifileucel) for Advanced Melanoma

* AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.
PHILADELPHIA, PA. - WuXi Advanced Therapies , a wholly owned subsidiary...

Related Keywords

San Carlos ,California ,United States ,Philadelphia ,Pennsylvania ,Wuxi ,Jiangsu ,China ,America ,Frederick Vogt ,Drug Administration ,Iovance Cell Therapy Center ,Nasdaq ,Iovance Biotherapeutics Inc ,Contract Research ,Navy Yard Philadelphia ,Manufacturing Organization ,Biologics License Application ,Chief Executive Officer ,Vice Chairman ,Cell Therapy Center ,Navy Yard ,Interim Chief Executive Officer ,Wuxi Advanced Therapies ,Contract Testing ,Markets ,